Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Immune Evasion Target Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CMTM6 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CMTM6 Extracellular Loop Recombinant Protein HEK293 expressed, High purity (>95%), Endotoxin <1 EU/μg. Sequence Verified. Ideal for ELISA and surface plasmon resonance (SPR) binding assays. |
View CMTM6 Products |
| Gene Delivery | CMTM6 Lentivirus Premade Particles Full-length human CMTM6 ORF. Optimized for stable cell line generation to preserve native 4-pass transmembrane conformation in flow cytometry and functional assays. |
View CMTM6 Products |
| Benchmark Ab | Anti-CMTM6 Recombinant Antibody High-affinity positive control derived from benchmark clones. Sequence verified for reproducible assay baselines. |
View CMTM6 Products |
| Validator | CMTM6 siRNA Set Target-specific knockdown pool for validating target dependency and antibody specificity in vitro. |
View CMTM6 Products |
| Related Target A | PD-L1 CMTM6 directly associates with and stabilizes PD-L1 at the cell surface, preventing its lysosomal degradation. |
View PD-L1 Products |
| Related Target B | CMTM4 A close paralog of CMTM6 that acts as a back-up regulator of PD-L1 expression, serving as a critical selectivity counter-screen target. |
View CMTM4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Loss of Multi-pass Membrane Target | Lentiviral transduction systems enable stable, high-level expression of full-length CMTM6 in host cell lines, preserving native folding. |
| Subfamily Cross-Reactivity (CMTM6 vs. CMTM4) | Sequence-verified recombinant extracellular loop proteins of both CMTM6 and CMTM4 are available for rigorous counter-screening. |
| Lack of Reliable Controls | Inclusion of sequence-defined recombinant clinical benchmark antibodies ensures consistent assay validation. |
| False Positive Binding Signals | Validated siRNA sets allow target-knockdown specificity verification in functional assays. |
Live CMTM6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CMTM6 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies and small-molecule/PROTAC degraders. As first-generation anti-PD-1/PD-L1 therapies encounter resistance, the next wave of R&D is targeting CMTM6 to prevent PD-L1 recycling and restore immune surveillance. By disrupting the physical interaction between CMTM6 and PD-L1, drug developers aim to synergize with existing checkpoint inhibitors and overcome refractory tumor microenvironments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Invenra, Pierre Fabre | Solid Tumors, NSCLC | Surface Binding & Blockade (Requires native cell-surface CMTM6 via Lentiviral transduction) |
| Bispecific / Multispecific | Light Chain Bioscience | Refractory Solid Tumors | Dual-Targeting Affinity Verification (Requires high-purity CMTM6 and PD-L1 proteins) |
| Small Molecule / PROTAC | Academic Institutions, Biotech Startups | Immunotherapy-Resistant Cancers | Interaction Disruption & Degradation Assay (Requires validated siRNA for target-validation controls) |